Review Article
Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents
Table 4
Pharmacokinetic parameters of some lead drugs.
| Drug | Available forms | Experimental organisms | Pharmacokinetic parameters | References | Oral bioavailability (%) | (μg/mL) | (h) | Protein binding (%) | Half time (h) | Elimination |
| E1210 | Oral/IVa | Mice | 57.5 | 0.11 | 0.5 | High | 2.2 | nrd | [80] | Albaconazole | Oral | Healthy human volunteers | nrd | 5–80 (proportional to dose) | 2–4 | 98 | 30–56 | Feces | [81, 82] | Isavuconazonium | Oral | Healthy human volunteers | Very high | 1.03 (100 mg dose) | 0.75–1 | 98 | 56–77 | Feces | [81–83] | Isavuconazole | IVa | Healthy human volunteers | nrd | 1.45 (100 mg dose) | 1.3–5 | 98 | 76–104 | Feces | [81–83] |
|
|
IV: intravenous; b: maximal concentration; c: time to reach maximal plasma concentrations after oral administration; dnr: not reported.
|